These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 20690782)

  • 1. Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model.
    Lahu G; Hünnemeyer A; Diletti E; Elmlinger M; Ruth P; Zech K; McCracken N; Facius A
    Clin Pharmacokinet; 2010 Sep; 49(9):589-606. PubMed ID: 20690782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of repeated dose of erythromycin on the pharmacokinetics of roflumilast and roflumilast N-oxide.
    Lahu G; Huennemeyer A; Herzog R; McCracken N; Hermann R; Elmlinger M; Zech K
    Int J Clin Pharmacol Ther; 2009 Apr; 47(4):236-45. PubMed ID: 19356389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steady-state pharmacokinetics of roflumilast and roflumilast N-oxide in patients with mild and moderate liver cirrhosis.
    Hermann R; Nassr N; Lahu G; Péterfai E; Knoerzer D; Herzog R; Zech K; de Mey C
    Clin Pharmacokinet; 2007; 46(5):403-16. PubMed ID: 17465639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide.
    Lahu G; Nassr N; Herzog R; Elmlinger M; Ruth P; Hinder M; Huennemeyer A
    J Clin Pharmacol; 2011 Apr; 51(4):586-93. PubMed ID: 20466871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and Pharmacodynamic Modelling to Characterize the Tolerability of Alternative Up-Titration Regimens of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease.
    Facius A; Marostica E; Gardiner P; Watz H; Lahu G
    Clin Pharmacokinet; 2018 Aug; 57(8):1029-1038. PubMed ID: 29797235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No dose adjustment on coadministration of the PDE4 inhibitor roflumilast with a weak CYP3A, CYP1A2, and CYP2C19 inhibitor: an investigation using cimetidine.
    Böhmer GM; Gleiter CH; Mörike K; Nassr N; Walz A; Lahu G
    J Clin Pharmacol; 2011 Apr; 51(4):594-602. PubMed ID: 20484614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of pharmacokinetic and pharmacodynamic interactions of roflumilast with (R, S)-warfarin in healthy adult subjects.
    McCracken N; Lahu G; Bethke TD
    Int J Clin Pharmacol Ther; 2011 Jun; 49(6):388-96. PubMed ID: 21612746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
    Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
    Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease.
    Rabe KF
    Br J Pharmacol; 2011 May; 163(1):53-67. PubMed ID: 21232047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of renal impairment on the pharmacokinetics of oral roflumilast: an open-label, parallel-group, single-center study.
    Bethke TD; Hartmann M; Hünnemeyer A; Lahu G; Gleiter CH
    Int J Clin Pharmacol Ther; 2011 Aug; 49(8):491-9. PubMed ID: 21781649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects.
    Nassr N; Huennemeyer A; Herzog R; von Richter O; Hermann R; Koch M; Duffy K; Zech K; Lahu G
    Br J Clin Pharmacol; 2009 Oct; 68(4):580-7. PubMed ID: 19843061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic evaluation of roflumilast.
    Lahu G; Nassr N; Hünnemeyer A
    Expert Opin Drug Metab Toxicol; 2011 Dec; 7(12):1577-91. PubMed ID: 22059647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of population pharmacokinetic modeling to explore the impact of alternative roflumilast dosing regimens on tolerability.
    Lahu G; Facius A
    Int J Clin Pharmacol Ther; 2013 Nov; 51(11):832-6. PubMed ID: 24152603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of fluvoxamine on the pharmacokinetics of roflumilast and roflumilast N-oxide.
    von Richter O; Lahu G; Huennemeyer A; Herzog R; Zech K; Hermann R
    Clin Pharmacokinet; 2007; 46(7):613-22. PubMed ID: 17596106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Single-center, Open-label, Parallel Control Study Comparing the Pharmacokinetics and Safety of a Single Oral Dose of Roflumilast and Its Active Metabolite Roflumilast N-oxide in Healthy Chinese and Caucasian Volunteers.
    Han M; Lin XY; Cui G; Chen S; Wu W; Mi N; Wang J; Xiao CY; Zhang X; Lu X; Li JT
    Clin Pharmacol Drug Dev; 2023 Mar; 12(3):314-323. PubMed ID: 36484261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roflumilast, a once-daily oral phosphodiesterase 4 inhibitor, lacks relevant pharmacokinetic interactions with inhaled salbutamol when co-administered in healthy subjects.
    Bethke TD; Giessmann T; Westphal K; Weinbrenner A; Hauns B; Hauschke D; David M; Lahu G; Zech K; Hermann R; Siegmund W
    Int J Clin Pharmacol Ther; 2006 Nov; 44(11):572-9. PubMed ID: 17176624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential role of roflumilast: the new phosphodiesterase-4 inhibitor.
    Karish SB; Gagnon JM
    Ann Pharmacother; 2006 Jun; 40(6):1096-104. PubMed ID: 16735669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of Roflumilast and Its Active Metabolite Roflumilast N-Oxide in Healthy Chinese Subjects After Single and Multiple Oral Doses.
    Li Q; Wang Y; Liu L; Ma P; Ding L
    Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):371-381. PubMed ID: 27306372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.
    Pinner NA; Hamilton LA; Hughes A
    Clin Ther; 2012 Jan; 34(1):56-66. PubMed ID: 22284994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
    Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.